



**November 5, 2025**

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001.  
**Ref:- Scrip Code:- 500126**

To,  
The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai – 400051  
**Ref:- Symbol:- PGHL**

Dear Sir / Madam,

**Sub: Press release on unaudited Financial Results for the quarter ended September 30, 2025**

We are enclosing herewith the Press Release, regarding the unaudited Financial Results for quarter ended September 30, 2025, approved at a meeting of the Board of Directors of the Company held today.

Kindly take the same on record.

Thanking you.  
Yours faithfully,

For **Procter & Gamble Health Limited**

**Zeal Rupani**  
Company Secretary



## Procter & Gamble Health Announces Second Quarter Results

*Sales up 3% and PAT up 8% for the quarter ended September 30, 2025*

**Mumbai, November 5, 2025:** Procter & Gamble Health Ltd. (PGHL) today announced its financial results for the second quarter ended September 30, 2025. The Company delivered sales of ₹319 crores, up 3% versus a year ago, driven by strong brand fundamentals and positive consumer response to new innovations. Profit After Tax (PAT) stood at ₹89 crores, up 8% versus a year ago, led by growth in sales.

**Mr. Milind Thatte, Managing Director, P&G Health India, said,** "We are pleased with the sustained growth momentum after a strong start to the Financial Year 2025-26, with balanced growth across both top-line and bottom-line for the second consecutive quarter. This is driven by strategic efforts across the value chain including a strategic consumer communication initiative on Evion and Seven Seas, and the introduction of new products like the Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream among others. Further, we continue to strengthen our supply chain capabilities, ensuring we are addressing the evolving needs of our consumers, customers and healthcare professionals, via superior brand building, go to market initiatives, and innovations backed by science."

**About Procter & Gamble Health Limited:** Procter & Gamble Health Limited is one of India's largest vitamins, minerals, and supplements (VMS) companies manufacturing and marketing VMS products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Please visit [www.pghealthindia.com](http://www.pghealthindia.com) for the latest news and information about Procter & Gamble Health Limited and its brands.

**About Procter & Gamble:** P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur®, Ariel®, Gillette®, Braun®, Head & Shoulders®, Olay®, Oral-B®, Pampers®, Pantene®, Herbal Essences®, Tide®, Vicks®, and Whisper®. P&G operates in approximately 70 countries worldwide.

### CONTACTS

#### Media Contacts - Procter & Gamble Health Limited:

Vishesh Bohre | [bohre.v@pg.com](mailto:bohre.v@pg.com)

#### Agency Contact – SPAG FINN Partners

Sarah Rajan | [sarah.rajan@finnpartners.com](mailto:sarah.rajan@finnpartners.com)

Desiree Crasto | [desiree.crasto@finnpartners.com](mailto:desiree.crasto@finnpartners.com)

#### Procter & Gamble Health Limited

CIN: L99999MH1967PLC013726

Registered Office: Ground Floor and First Floor,  
P&G Plaza, Cardinal Gracias Road, Chakala,  
Andheri-E, Mumbai-400 099 | Tel: (91-22) 6866 9000  
[www.pghealthindia.com](http://www.pghealthindia.com)